High efficacy of praziquantel in the treatment of 22 patients with Clonorchis/Opisthorchis infections.
In a prospective clinical study, the efficacy of praziquantel in the treatment of 22 patients with Clonorchis/Opisthorchis infections was investigated. The dose regimen was 90 mg per kg bodyweight, divided into three equal doses given on consecutive days. Parasitological, clinical, routine haematological and biochemical parameters were followed up for twelve months. Twenty patients (91%) had no detectable egg excretion in the feces or duodenal fluid after one treatment only. Two patients required repeated treatments and a different dose regimen. No serious side effects were observed. Praziquantel proved to be a safe and effective drug for therapy of Clonorchis/Opisthorchis infections.
D000293:Adolescent; D000328:Adult; D000818:Animals; D001826:Body Fluids / Q000469:parasitology; D003003:Clonorchiasis / Q000188:drug therapy*; D004341:Drug Evaluation; D004386:Duodenum; D005243:Feces / Q000469:parasitology; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008297:Male; D009889:Opisthorchiasis / Q000188:drug therapy*; D010270:Parasite Egg Count; D011223:Praziquantel / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies
D007546:Isoquinolines; D011223:Praziquantel